BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ), ein Pharmaunternehmen mit einer Marktkapitalisierung von 13,15 Milliarden US-Dollar, gab am Montag die Ernennung von Timothy P. Walbert in seinen Vorstand ...
Oppenheimer upgraded Biomarin Pharmaceutical (TADAWUL:2070) Inc (NASDAQ:BMRN) to "Outperform" from "Perform," citing strong fourth-quarter results and increasing confidence in the company's long-term ...
The 2024 Uganda Bureau of Statistics census report indicates that 5.7 per cent of the population has a disability showing a ...
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
Die Analysten von Oppenheimer haben am Montag ihre Einschätzung der BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Aktie von "Perform" auf "Outperform" angehoben und ein Kursziel von 98,00 US-Dollar fest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback